Graham R. Foster

Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3

T. Asselah, M. Stepanova, L. Henry, 2018, Alimentary pharmacology & therapeutics.

Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries.

F. Tacke, V. de Lédinghen, M. Buti, 2023, Journal of hepatology.

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

A. Mangia, G. Dore, S. Zeuzem, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3

M. Torbenson, S. Zeuzem, D. Nelson, 2011, Gut.

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

P. Thuluvath, D. Mutimer, C. Hézode, 2018 .

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

John F. Flaherty, G. Foster, K. Agarwal, 2015, Journal of hepatology.

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

T. Pilot‐Matias, G. Foster, K. Agarwal, 2018, Journal of viral hepatitis.

Joint statement in support of hepatitis C human challenge studies.

Daniel M. Haybron, S. Pinker, G. Lauer, 2023, The lancet. Gastroenterology & hepatology.